Sep 17, 2025 04:06PM Vaxart names W. Mark Watson as lead independent director

Aug 29, 2025 08:01AM Vaxart granted extension to meet NASDAQ bid price requirement

Aug 13, 2025 04:09PM Vaxart (VXRT) Tops Q2 EPS by 2c

Jun 11, 2025 07:30AM Vaxart (VXRT) Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

May 29, 2025 08:02AM Vaxart (VXRT) Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 16, 2025 08:04AM Vaxart (VXRT) Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

May 15, 2025 08:01AM Vaxart (VXRT) Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 13, 2025 04:21PM Vaxart (VXRT) Tops Q1 EPS by 4c

May 13, 2025 04:02PM Vaxart (VXRT) Appoints Jeroen Grasman as CFO

May 5, 2025 08:01AM Vaxart (VXRT) CEO Issues Letter to Stockholders Highlighting Company Progress

Apr 30, 2025 08:01AM Vaxart (VXRT) Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Mar 20, 2025 04:21PM Vaxart (VXRT) Misses Q4 EPS by 23c

Mar 5, 2025 04:06PM Vaxart (VXRT) Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Feb 24, 2025 03:06PM Oppenheimer Reiterates Outperform Rating on Vaxart Inc. (VXRT)

Feb 10, 2025 05:03PM Vaxart secures $105.9 million more for COVID-19 pill vaccine trial

Jan 28, 2025 08:02AM Vaxart (VXRT) Appoints Kevin Finney to its Board

Jan 14, 2025 08:07AM Vaxart (VXRT) Highlights Progress of COVID-19, Norovirus and Influenza Programs

Nov 13, 2024 04:03PM Vaxart (VXRT) Tops Q3 EPS by 4c

Aug 28, 2024 08:01AM Vaxart (VXRT) Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dys

Aug 8, 2024 04:17PM Vaxart (VXRT) Tops Q2 EPS by 6c

Jun 17, 2024 04:06PM Vaxart (VXRT) Provides Business Update

Jun 17, 2024 05:13AM Vaxart (VXRT) call put ratio 17.6 calls to 1 put

Jun 14, 2024 07:35AM Vaxart Inc. (VXRT) PT Raised to $2.50 at B.Riley

Jun 14, 2024 05:59AM Vaxart (VXRT) Announces 50M Share Offering at $0.80/sh

Jun 14, 2024 04:39AM Vaxart (VXRT) 30-day option implied volatility above 100

Jun 13, 2024 05:01PM After-hours movers: Adobe, RH, GME, and more

Jun 13, 2024 04:15PM Vaxart (VXRT) Receives BARDA-Funded Award Valued Up to $453M for Phase 2b Study of COVID-19 Oral Pill Vaccine Candidate